RGLS - Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.